Clinical Trials Browser

Phase 2 × Interventional × cc-486 × Clear all

NCT05197426 2026-02-11

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Phase 2 Active not recruiting

19 enrolled 24 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04174196 2025-12-02

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

Phase 2 Active not recruiting

Multiple Myeloma, Plasmacytoma

NCT02546986 2025-08-08

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2 Completed

100 enrolled 27 charts

Carcinoma, Non-Small-Cell Lung

NCT02494258 2025-05-22

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Phase 2 Completed

Other hematologic neoplasm

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

NCT06022003 2025-03-24

OGILAR

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Phase 2 Terminated

54 enrolled 26 charts

Myeloid Malignancies

NCT02250326 2024-09-19

abound2L+

Phase 2 Completed

240 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT03493646 2024-05-28

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Phase 2 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06180863 2023-12-26

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Phase 2 Withdrawn

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01845805 2022-10-04

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)

Phase 2 Completed

49 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02900560 2022-06-10

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

Phase 2 Terminated

34 enrolled 15 charts

Carcinoma, Ovarian Epithelial

NCT02811497 2021-04-01

METADUR

Phase 2 Completed

BreastGastrointestinalGynecologic

Microsatellite Stable Colorectal Carcinoma

NCT02374099 2018-12-14

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

Phase 2 Terminated

97 enrolled 18 charts

Breast Neoplasms

NCT02269943 2018-12-12

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Phase 2 Completed

36 enrolled 24 charts

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Epstein-Barr Virus Infections